MedTrace Logo

Study of Personalized Cancer Therapy to Determine Response and Toxicity

NCT02478931 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-03-31

No results posted yet for this study

Summary

The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whether or not patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor. Optional research tests may be performed on tissue, body cavity fluid, blood or urine provided, discarded biological samples taken during routine care that would normally be disposed of and not saved, or on blood samples collected for this study. These research tests will be used to create a "profile" of the collected specimens which will describe unique characteristics about the genes involved in a person's cancer. The tests will also help researchers look for biomarkers that may help predict how people respond to treatment.

Conditions

Sponsors & Collaborators

  • Shu Mei Kato

    lead OTHER

Principal Investigators

  • Shumei Kato, MD · University of California, San Diego

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-05
Primary Completion
2026-09-05
Completion
2027-09-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02478931 on ClinicalTrials.gov